Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 837.60M | 753.20M | 678.40M | 690.60M | 557.00M |
Gross Profit | 585.40M | 517.00M | 476.40M | 493.00M | 378.80M |
EBITDA | -59.50M | -186.10M | -67.80M | 14.10M | -123.40M |
Net Income | -127.30M | -263.30M | -112.00M | -27.20M | -223.70M |
Balance Sheet | |||||
Total Assets | 1.03B | 1.15B | 1.20B | 1.32B | 1.42B |
Cash, Cash Equivalents and Short-Term Investments | 102.40M | 140.90M | 114.90M | 339.80M | 150.70M |
Total Debt | 140.30M | 152.10M | 145.00M | 92.30M | 0.00 |
Total Liabilities | 326.50M | 363.30M | 312.90M | 352.90M | 537.80M |
Stockholders Equity | 701.10M | 783.20M | 885.80M | 967.80M | 881.00M |
Cash Flow | |||||
Free Cash Flow | -38.40M | -184.20M | -151.60M | 600.00K | -40.10M |
Operating Cash Flow | -8.70M | -110.90M | -106.30M | 18.60M | -26.90M |
Investing Cash Flow | -11.90M | 31.90M | -77.50M | 274.40M | 61.60M |
Financing Cash Flow | -7.40M | 152.90M | -8.00M | -150.60M | -1.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | $730.53M | 11.39 | 21.57% | ― | 25.92% | ― | |
64 Neutral | $471.20M | 30.59 | -1.20% | ― | 38.43% | 86.19% | |
58 Neutral | $1.34B | ― | -62.22% | ― | 30.47% | -26.63% | |
52 Neutral | $7.61B | 0.04 | -62.94% | 2.44% | 16.14% | 0.33% | |
52 Neutral | $567.16M | ― | -3.61% | ― | 1.71% | 76.00% | |
51 Neutral | $826.22M | ― | -8.57% | ― | 10.10% | 8.79% | |
43 Neutral | $423.09M | ― | -13.84% | ― | 7.38% | 60.45% |
Myriad Genetics has resolved a series of shareholder derivative lawsuits alleging fiduciary breaches by former and current directors. The settlement, approved by the Delaware Court, includes corporate governance reforms and a $950,000 attorney fee award, with no admission of wrongdoing by the parties involved. This agreement may reassure investors, highlighting efforts to strengthen oversight and governance within the company.